Purple Biotech Ltd
PPBT
$3.95
$0.102.55%
NASDAQ
| 12/31/2025 | 06/30/2025 | 12/31/2024 | 09/30/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -68.37% | 63.33% | |
| Gross Profit | -- | -- | 68.37% | -63.33% | |
| SG&A Expenses | -- | -- | -36.74% | -38.62% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -- | -- | -51.19% | -28.25% | |
| Operating Income | -- | -- | 51.19% | 28.25% | |
| Income Before Tax | -- | -- | 63.56% | 44.60% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -- | -- | 63.56% | 44.60% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -59.79% | -33.67% | |
| Net Income | -- | -- | 63.58% | 44.65% | |
| EBIT | -- | -- | 51.19% | 28.25% | |
| EBITDA | -- | -- | 51.53% | 28.32% | |
| EPS Basic | -- | -- | 71.95% | 58.82% | |
| Normalized Basic EPS | -- | -- | 79.18% | 52.42% | |
| EPS Diluted | -- | -- | 72.01% | 58.63% | |
| Normalized Diluted EPS | -- | -- | 79.18% | 52.42% | |
| Average Basic Shares Outstanding | -- | -- | 47.31% | 41.96% | |
| Average Diluted Shares Outstanding | -- | -- | 47.31% | 41.96% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |